Tirzepatide: the dual-agonist.

Tirzepatide is probably the most-discussed peptide outside of research circles right now. Unlike most compounds we cover here, it is actually FDA-approved for clinical use — which puts it in a different category from the rest. Here is what it is, what it does, and the honest picture.

What makes tirzepatide different

Most of the compounds covered in this series are research peptides — studied, but not approved for clinical use. Tirzepatide is different. It is approved by the FDA under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It went through full clinical trials and received regulatory clearance based on substantial human evidence.

That regulatory status is genuinely important. It does not mean tirzepatide is risk-free or appropriate for everyone, but it does mean the clinical evidence base is far deeper than for most peptides discussed in research communities.

How it works

Tirzepatide is a dual agonist — it activates two different receptors in the body that play roles in metabolism and appetite. The first is the GLP-1 receptor (the same target as semaglutide and earlier GLP-1 medications). The second is the GIP receptor, which earlier compounds did not target.

Both GLP-1 and GIP are natural hormones your gut releases when you eat. They help regulate blood sugar, slow stomach emptying, signal fullness to the brain, and influence how the body stores and uses fat. By activating both receptors at once, tirzepatide produces effects that have been substantially stronger than older single-agonist medications in head-to-head trials.

What clinical research has shown

Because tirzepatide is approved, there is a much more robust clinical evidence base than for research peptides:

• Glycemic control — significant reductions in HbA1c in people with type 2 diabetes.
• Weight reduction — average weight reductions of around 15 to 22 percent in trial participants over 72 weeks (varies by dose).
• Cardiometabolic markers — improvements in blood pressure, lipids, and inflammatory markers in trials.
• Side effect profile — most commonly gastrointestinal (nausea, reduced appetite, occasional vomiting), particularly during dose escalation.

The bigger picture

Tirzepatide sits at the intersection of established medicine and the broader peptide conversation. It is a useful reference point for understanding why GLP-1-style compounds have captured so much attention: the clinical effects are genuinely substantial, and the science behind them — working with gut-derived signaling hormones rather than against the body's own pathways — represents a real shift in how metabolic medicine is approaching weight and glucose regulation.

If you are working with reconstitution math for tirzepatide specifically, the calculator handles it (it is one of the preset peptides, with a 10mg / 2mL / 2.5mg weekly starting reference). And the injection site map shows the rotation sites commonly used for weekly GLP-1-style dosing.